NCT05677633View on ClinicalTrials.gov

Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

April 12, 2024

Study Completion Date

November 1, 2024

Conditions
Parkinson's Disease and Parkinsonism
Interventions
DRUG

Sargramostim

Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

Sponsors
All Listed Sponsors
collaborator

Partner Therapeutics, Inc.

INDUSTRY

lead

University of Nebraska

OTHER